22-50074296-C-T
Variant summary
Our verdict is Pathogenic. Variant got 24 ACMG points: 24P and 0B. PS1_Very_StrongPM2PM5PP3_StrongPP5_Very_Strong
The NM_015166.4(MLC1):c.634G>A(p.Gly212Arg) variant causes a missense change. The variant allele was found at a frequency of 0.00000137 in 1,461,788 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another nucleotide change resulting in same amino acid change has been previously reported as Likely pathogenicin ClinVar. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G212E) has been classified as Likely pathogenic.
Frequency
Consequence
NM_015166.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 24 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
MLC1 | NM_015166.4 | c.634G>A | p.Gly212Arg | missense_variant | 8/12 | ENST00000311597.10 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
MLC1 | ENST00000311597.10 | c.634G>A | p.Gly212Arg | missense_variant | 8/12 | 1 | NM_015166.4 | P1 | |
MLC1 | ENST00000395876.6 | c.634G>A | p.Gly212Arg | missense_variant | 8/12 | 1 | P1 | ||
MLC1 | ENST00000442311.1 | c.544G>A | p.Gly182Arg | missense_variant | 7/8 | 5 | |||
MLC1 | ENST00000470008.1 | n.114G>A | non_coding_transcript_exon_variant | 2/3 | 3 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.00000399 AC: 1AN: 250780Hom.: 0 AF XY: 0.00000737 AC XY: 1AN XY: 135760
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461788Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 727194
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Megalencephalic leukoencephalopathy with subcortical cysts 1 Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Mar 22, 2022 | Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000068794,VCV000553381, PMID:11254442). The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least 2 similarly affected unrelated individuals (PMID: 11254442, 21145992, 27322623). Functional assays showed that the variant had moderate level of impact on gene/protein function (PMID: 15367490, 18757878). Different pathogenic/likely pathogenic amino acid change has been reported with supporting evidence at the same codon (PMID:11935341). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.902>=0.6, 3CNET: 0.797>=0.75). The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.0000040). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Pathogenic, criteria provided, single submitter | research | Rare Genetic Disease Lab, Dept of Zoology, Government Postgraduate College Dargai Malakand, Higher Education Govt. of Khyber Pakhtunkhwa | Dec 06, 2022 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Jul 22, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Jan 02, 2024 | Criteria applied: PS1,PS3,PM3,PM5,PM2_SUP,PP4 - |
not provided Pathogenic:1Other:1
not provided, no classification provided | literature only | UniProtKB/Swiss-Prot | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jun 28, 2022 | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Gly212 amino acid residue in MLC1. Other variant(s) that disrupt this residue have been observed in individuals with MLC1-related conditions (PMID: 11254442, 11935341, 21145992, 27322623), which suggests that this may be a clinically significant amino acid residue. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Studies have shown that this missense change alters MLC1 gene expression (PMID: 18757878). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MLC1 protein function. ClinVar contains an entry for this variant (Variation ID: 68794). This missense change has been observed in individuals with megalencephalic leukoencephalopathy with subcortical cysts (PMID: 11254442, 21145992, 27322623). This variant is present in population databases (rs281875317, gnomAD 0.0009%). This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 212 of the MLC1 protein (p.Gly212Arg). - |
Megalencephalic leukoencephalopathy with subcortical cysts Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | May 05, 2023 | Variant summary: MLC1 c.634G>A (p.Gly212Arg) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 250780 control chromosomes. c.634G>A has been reported in the literature in homozygous and compound heterozygous individuals affected with Megalencephalic Leukoencephalopathy With Subcortical Cysts 1 (Leegwater_2001, Yuzbasioglu_2011, Cao_2016) with second reported alleles both pathogenic and uncertain significance. These data indicate that the variant is likely to be associated with disease. One publication reports experimental evidence showing severely reduced (<10% WT levels) presence of the protein at the plasma membrane, however, does not allow convincing conclusions about the variant effect (Duarri_2008). The following publications have been ascertained in the context of this evaluation (PMID: 27322623, 18757878, 11254442, 21145992). Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic (n=2) or likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at